NovaGo Therapeutics, founded in 2015 in Schlieren, Switzerland, is a development-stage biotech company specializing in human antibody therapeutics aimed at promoting blood vessel and nerve growth. The company is focused on creating innovative treatments for cerebral stroke, spinal cord injury, and diabetic retinopathy (DR), a leading cause of blindness in adults and a common complication of Type 1 and Type 2 Diabetes. NovaGo's proprietary human antibodies have the potential to become safe and effective treatments in both ophthalmology and central nervous system indications. The company's business model revolves around the research and development of these therapeutic antibodies, with plans to initiate clinical development for its lead molecule targeting diabetic retinopathy. NovaGo generates revenue through partnerships, grants, and future commercialization of its therapeutic solutions.

Keywords: human antibody therapeutics, nerve repair, blood vessel growth, diabetic retinopathy, cerebral stroke, spinal cord injury, ophthalmology, central nervous system, biotech, clinical development.